{"entity":{"id":"prkcz","kind":"target","name":"PRKCZ","aka":["protein kinase C zeta","Protein kinase C zeta type","PKC2"],"tldr":"PRKCZ (Protein kinase C zeta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","summary":"Calcium- and diacylglycerol-independent serine/threonine-protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein (MAP) kinase cascade, and is involved in NF-kappa-B activation, mitogenic signalling, cell proliferation, cell polarity, inflammatory response and maintenance of long-term potentiation (LTP). Upon lipopolysaccharide (LPS) treatment in macrophages, or following mitogenic stimuli, functions downstream of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signalling cascade independently of RAF1 activation. Required for insulin-dependent activation of AKT3, but may function as an adapter rather than a direct activator.\n\nOpen Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.93, animal model 0.32, genetic association 0.37, clinical 0.92).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9412","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9412"},{"label":"UniProt Q05513","url":"https://www.uniprot.org/uniprotkb/Q05513/entry"},{"label":"NCBI Gene 5590","url":"https://www.ncbi.nlm.nih.gov/gene/5590"},{"label":"Ensembl ENSG00000067606","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000067606"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["leukaemia","myeloproliferative-neoplasms","systemic-mastocytosis","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.94. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PRKCZ","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9412","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9412","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q05513","url":"https://www.uniprot.org/uniprotkb/Q05513/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000067606","url":"https://platform.opentargets.org/target/ENSG00000067606/associations","note":"association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.56, myeloproliferative neoplasm 0.56, systemic mastocytosis 0.54, leukaemia 0.57 (GraphQL API, CC0)"}],"hgnc":"HGNC:9412","ensembl":"ENSG00000067606","uniprot":"Q05513","entrez":"5590","biology":"Calcium- and diacylglycerol-independent serine/threonine-protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein (MAP) kinase cascade, and is involved in NF-kappa-B activation, mitogenic signalling, cell proliferation, cell polarity, inflammatory response and maintenance of long-term potentiation (LTP). Upon lipopolysaccharide (LPS) treatment in macrophages, or following mitogenic stimuli, functions downstream of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signalling cascade independently of RAF1 activation. Required for insulin-dependent activation of AKT3, but may function as an adapter rather than a direct activator. Upon insulin treatment may act as a downstream effector of PI3K and contribute to the activation of translocation of the glucose transporter SLC2A4/GLUT4 and subsequent glucose transport in adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity and can activate JUN promoter through MEF2C. Through binding with SQSTM1/p62, functions in interleukin-1 signalling and activation of NF-kappa-B with the specific adapters RIPK1 and TRAF6. Location: Cytoplasm; Endosome; Cell junction; Membrane (UniProt). Locus 1p36.33 (HGNC).","whereFound":["Leukaemia: Open Targets association 0.57 with leukaemia (MONDO_0005059)","Myeloproliferative neoplasms: Open Targets association 0.56 with myeloproliferative neoplasm (MONDO_0020076)","Systemic mastocytosis: Open Targets association 0.54 with systemic mastocytosis (MONDO_0016586)","Acute myeloid leukaemia: Open Targets association 0.56 with acute myeloid leukaemia (MONDO_0018874)"],"targetClass":"kinase","prevalence":[]},"route":"/targets/prkcz/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/"}]}}